Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective

被引:3
|
作者
Andrew, Peter [1 ]
Vickers, Michael M. [1 ]
O'Connor, Stephen [2 ]
Valdes, Mario [3 ]
Tang, Patricia A. [4 ]
机构
[1] Univ Ottawa, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada
[2] City Univ London, London EC1V 0HB, England
[3] Grand River Reg Canc Ctr, Kitchener, ON, Canada
[4] Univ Calgary, Dept Med Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源
ONCOLOGIST | 2016年 / 21卷 / 03期
关键词
Clinical trials; Journalism; Neoplasms; Social media; TRASTUZUMAB PLUS DOCETAXEL; CANCER-PATIENTS; GOOGLE-SCHOLAR; NEWS MEDIA; DOUBLE-BLIND; INTERNET USE; TWITTER USE; PHASE-III; CHEMOTHERAPY; CITATIONS;
D O I
10.1634/theoncologist.2015-0056
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Media reporting of clinical trials impacts patient-oncologist interactions. We sought to characterize the accuracy of media and Internet reporting of practice-changing clinical trials in oncology. Materials and Methods. The first media articles referencing 17 practice-changing clinical trials were collected from 4 media outlets: newspapers, cable news, cancer websites, and industry websites. Measured outcomes were media reporting score, social media score, and academic citation score. The media reporting score was a measure of completeness of information detailed in media articles as scored by a 15-point scoring instrument. The social media score represented the ubiquity of social media presence referencing 17 practice-changing clinical trials in cancer as determined by the American Society of Clinical Oncology in its annual report, entitled Clinical Cancer Advances 2012; social media score was calculated from Twitter, Facebook, and Google searches. The academic citation score comprised total citations from Google Scholar plus the Scopus database, which represented the academic impact per clinical cancer advance. Results. From 170 media articles, 107 (63%) had sufficient data for analysis. Cohen's kappa coefficient demonstrated reliability of the media reporting score instrument with a coefficient of determination of 94%. Per the media reporting score, information was most complete from industry, followed by cancer websites, newspapers, and cable news. The most commonly omitted items, in descending order, were study limitations, exclusion criteria, conflict of interest, and other. The social media score was weakly correlated with academic citation score. Conclusion. Media outlets appear to have set a low bar for coverage of many practice-changing advances in oncology, with reports of scientific breakthroughs often omitting basic study facts and cautions, which may mislead the public. The media should be encouraged to use a standardized reporting template and provide accessible references to original source information whenever feasible.
引用
收藏
页码:269 / 278
页数:10
相关论文
共 50 条
  • [21] ELDERLY PATIENTS WITH ADVANCED NSCLC IN PHASE III CLINICAL TRIALS: ARE THE ELDERLY EXCLUDED FROM PRACTICE-CHANGING TRIALS IN ADVANCED NSCLC?
    Sacher, Adrian
    Leighl, Natasha
    Coate, Linda
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1219 - S1219
  • [22] European Society for Medical Oncology Copenhagen update: potential practice-changing findings
    Mallarkey, Gordon
    Grothey, Axel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (01) : 4 - 12
  • [23] Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?
    Sacher, Adrian G.
    Le, Lisa W.
    Leighl, Natasha B.
    Coate, Linda E.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 366 - 368
  • [24] Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials
    Nasso, Cecilia
    Puglisi, Silvia
    Rebuzzi, Sara Elena
    Errigo, Veronica
    Rosa, Francesca
    Chiola, Ilaria
    Lazzari, Caterina
    Musizzano, Yuri
    Venturino, Ezio
    Gastaldo, Alessandro
    Siccardi, Caterina
    Volpi, Eugenio Oreste
    Mammoliti, Serafina
    Benasso, Marco
    IMMUNOTHERAPY, 2025, 17 (01) : 57 - 66
  • [25] Bias in reporting of randomised clinical trials in oncology
    Vera-Badillo, Francisco E.
    Napoleone, Marc
    Krzyzanowska, Monika K.
    Alibhai, Shabbir M. H.
    Chan, An-Wen
    Ocana, Alberto
    Seruga, Bostjan
    Templeton, Arnoud J.
    Amir, Eitan
    Tannock, Ian F.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : 29 - 35
  • [26] Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016–2017
    Andrea Cervi
    James Demetrios Douketis
    Internal and Emergency Medicine, 2019, 14 : 355 - 363
  • [27] Moving Away From Axillary Lymph Node Dissection Indicates Practice-Changing Trials
    Batsis, Charalambos
    Zoras, Odysseas
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S281 - S282
  • [28] Extrapolation of clinical trials into oncology practice
    Fey, M.
    ONKOLOGIE, 2011, 34 : 4 - 4
  • [29] Moving Away From Axillary Lymph Node Dissection Indicates Practice-Changing Trials
    Charalambos Batsis
    Odysseas Zoras
    Annals of Surgical Oncology, 2011, 18 : 281 - 282
  • [30] Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016-2017
    Cervi, Andrea
    Douketis, James Demetrios
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (03) : 355 - 363